Maximize Your Returns with AI-Powered BMY Insights

Trade smarter with daily optimized BMY trades + news analysis


Bullish Case: BMY is positioned in a growing biotechnology market which projects at an 11.13% CAGR from 2023 to 2030[seedance.com]. Promising new Zeposia data[news.bms.com], an attractive 4% dividend yield[seekingalpha.com] and another drug Golcadomide in Phase II for Primary CNS Lymphoma[pharmaceutical-technology.com] show growth potential.

Show historical bullish cases

Bearish Case: BMY is currently at -34.4% from a year ago[Helium], with an unfavourable HeliumTrades AI price forecast[Helium]. Risks include stock concentration[seekingalpha.com], insider selling activity[Yahoo], and potential patent expirations[seekingalpha.com] which could harm future profits.

Show historical bearish cases

Takeaway: Unfavorable market sentiment around BMY, shown by the declining share price and insider selling[Yahoo, Helium], poses a challenge. However, the underpinning factors of new promising drug developments[news.bms.com, pharmaceutical-technology.com] and a healthy dividend yield[seekingalpha.com] indicate potential for future rewards notwithstanding potential risks.

Show historical takeaways

Potential Outcomes:

1. Successful drug developments(e.g Zeposia[news.bms.com], and Golcadomide[pharmaceutical-technology.com]) drive revenue growth and share price appreciation (60%). Strengths lie in the growing global biotech market[seedance.com] and BMY's innovative capabilities[Helium].

2. The effect of insider selling activity spooks investors, leading to a decrease in value, despite strong drug prospects. This could cause a drop in liquidity, but has potential to recover if future results are presented positively (30%)[Yahoo].

3. Low trading volumes due to mixed market sentiment keep the stock price stagnant - despite news of progress from its drug pipelines. This could be exacerbated by any negative news from competitors or the healthcare sector (10%)[Helium].


November 14, 2023


Bristol-Myers Squibb Forecast

[BMY]  Bristol-Myers Squibb
Price Forecast: BEARISH    Price Action: RANDOM (?)

4 Day Price Forecast + Historical Performance.  Video Tutorial: Trade Smarter With Helium's AI Forecasts

9 Day Price Forecast + Historical Performance.  Video Tutorial: Trade Smarter With Helium's AI Forecasts

20 Day Price Forecast + Historical Performance.  Video Tutorial: Trade Smarter With Helium's AI Forecasts

36 Day Price Forecast + Historical Performance.  Video Tutorial: Trade Smarter With Helium's AI Forecasts

49 Day Price Forecast + Historical Performance.  Video Tutorial: Trade Smarter With Helium's AI Forecasts



Make More Profitable Trades with BMY Forecasts + Trading Strategies






BMY Balanced News:


Futures Flat After OpenAI "Train Wreck" As Markets Brace For Nvidia Earnings

politics

US stock futures erased earlier losses to trade flat as Microsoft gained 2% in premarket trading, sending it to a new all time high, after it said Sam Altman will lead the software developer’s new in-house artificial intelligence team. The OpenAI co-founder was ousted from his startup last week.

ZeroHedge Opinion     Nov 20, 2023


Twin Crisis Rocks Bayer, Shares Crash Most On Record, Hitting Levels Not Seen Since GFC

politics

Bayer shares in Germany experienced their largest-ever intra-day crash, tumbling as much as 21% to lows not seen since the Great Financial Crisis, following a double whammy of news:

ZeroHedge Opinion     Nov 20, 2023


Bristol-Myers Squibb sees highest filings and grants during August ... - Pharmaceutical Technology

Bristol-Myers Squibb saw the highest growth of 156% in patent filings in August and 104% in grants in September in Q3 2023. Compared to Q2 2023, Q3 2023 saw an increase in patent filings by 56% and grants by 91%. GlobalData’s DataBook provides a comprehensive analysis of Bristol-Myers Squibb‘s patent filings and grants. Buy the databook here.

pharmaceutical-technology.com     Nov 24, 2023


Bristol-Myers Squibb: A Tough But Cheap Spot

Over the summer, I believed that Bristol-Myers Squibb Company (NYSE:BMY) was facing and battling exclusivity headwinds. The company was battling the loss of exclusivity of Revlimid, as it was trying to offset this loss of exclusivity with some new product engines, with growth desperately needed as more exclusivity expirations were upcoming later this decade.

seekingalpha.com     Nov 21, 2023


Markets News, Nov. 20, 2023: Microsoft Closes at Record, Leads ... - Investopedia

Colin is an Associate Editor focused on tech and financial news. He has more than three years of experience editing, proofreading, and fact-checking content on current financial events and politics. He received his M.A. in journalism from The New School and his B.A. in history and political science from McGill University.

investopedia.com     Nov 20, 2023







Correlated Stock Forecasts

Assets that tend to move strongly with BMY


MRNA Forecast + Options Trading Strategies   [MRNA]  Moderna (0.96)


ETSY Forecast + Options Trading Strategies   [ETSY]  Etsy (0.94)


QURE Forecast + Options Trading Strategies   [QURE]  uniQure (0.94)


A Forecast + Options Trading Strategies   [A]  Agilent (0.94)


ENB Forecast + Options Trading Strategies   [ENB]  Enbridge (0.93)



Uncorrelated Stock Forecasts

Assets with little price relationship to BMY


VGK Forecast + Options Trading Strategies   [VGK]  Vanguard FTSE Europe (-0.0)


PK Forecast + Options Trading Strategies   [PK]  Park Hotels & Resorts (-0.0)


XLE Forecast + Options Trading Strategies   [XLE]  Energy Select Sector SPDR (-0.01)


JDST Forecast + Options Trading Strategies   [JDST]  Direxion Daily Junior Gold Miners Index Be (-0.01)


AMGN Forecast + Options Trading Strategies   [AMGN]  AMGEN (-0.01)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against BMY


FTI Forecast + Options Trading Strategies   [FTI]  TechnipFMC (-0.91)


DKNG Forecast + Options Trading Strategies   [DKNG]  DraftKings (-0.91)


DXJ Forecast + Options Trading Strategies   [DXJ]  WisdomTree Japan Hedged Equity (-0.92)


SPOK Forecast + Options Trading Strategies   [SPOK]  Spok (-0.92)


RELY Forecast + Options Trading Strategies   [RELY]  Remitly (-0.93)